Investing in opportunities to improve health through innovation is a key driver of solutions for today\'s most difficult healthcare problems. Astellas Venture Management (AVM) /Innovation Management (\'AIM\') are interested in
Investing in opportunities to improve health through innovation is a key driver of solutions for today\’s most difficult healthcare problems. Astellas Venture Management (AVM) /Innovation Management (\’AIM\’) are interested in supporting early stage opportunities to advance the creation of human therapeutics. AVM/AIM will be presenting at Johnson and Johnson Innovation, JLABS on September 9th, 2015.
AVM is the venture group within one of Japan\’s second largest pharmaceutical company, Astellas Pharma Inc. You may be familiar with some of AVM\’s successful, local portfolio companies including eFFECTOR Therapeutics and Fate Therapeutics. With hundreds of millions in an evergreen fund, AVM is looking to invest in more private companies in the early stage drug discovery and platform technology across several therapeutic areas, including:
- Immunology and Inflammation, Urology, Oncology, Nephrology and Neuroscience
- Ophthalmology, Hearing Loss, Muscle disorder and Regenerative Medicine.
Also, AVM has another mission by AIM to execute early stage innovative collaborations with Academia and biotech companies. Recent collaboration deals include MD Anderson Cancer Center (oncology drug discovery), Potenza (Immune oncology drug discovery) and Kanyos Therapeutics (Autoimmune drug discovery). AVM/AIM will provide equity and non-dilutive capitals to our portfolios and partners while actively looking for innovative new opportunities.
Representatives from AVM/AIM will be in attendance to give an overview presentation on the company\’s key areas of interest and best practices when seeking funding. Following the presentation, don\’t miss this opportunity to network with fellow attendees and the AVM/AIM representatives during lunch. For those companies who apply online and receive approval, one-on-one meetings with AVM will provide a private forum to discuss your company.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on August 5th.
AVM Participating Representatives:
Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management read bio»
Takashi Futami | Associate Investment Director, Astellas Venture Management read bio»
Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management read bio»
Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Managementread bio»
Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Managementread bio»
(Wednesday) 10:30 am - 12:30 pm